Advent of artificial blood has eliminate the dependency on donor blood supplies

 

Artificial Blood 

Synthetic blood is manufactured by mixing synthetic hemoglobin with water and electrolytes. After completing the manufacturing process, the blood is pasteurized and packaged. Throughout the process, the compounds are tested for quality. During the production process, frequent checks are made on the culture of the bacteria and various physical and chemical properties of the finished product. Today, there are factories that can produce large batches of artificial blood.

According to Coherent Market Insights the Artificial Blood Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

One of the biggest benefits of artificial blood is its lack of dependency on donor blood supplies. Its universal blood group O negative characteristics help it avoid the problems associated with donor blood, such as shelf life. While donor blood can be stored for as long as 42 days before being used, it starts to lose quality soon after collection. Another benefit is that it does not require any biological materials. Its ability to dissolve more oxygen than blood plasma is what makes it attractive for use in the emergency situation. As perfluorocarbons are biologically inert, they are cheaper to produce. This also eliminates any risk of transmission of infectious diseases. However, despite the benefits of synthetic blood, these products still have a long way to go. There are two different types currently under research.

Until recently, the use of animal blood was not widely used in emergency situations. Originally, doctors used animal plasma and hemoglobin for blood transfusions. However, this approach proved to be ineffective, due to several technological issues. Scientists found it difficult to extract large amounts of hemoglobin and animal products were contaminated with toxic materials. As such, blood transfusions with animal products have never gained wide appeal. However, many scientists believe that artificial blood will be the next step in saving lives. Moreover, the cost of recombinant hemoglobin is too expensive to match that of blood-derived hemoglobin. Once the strains are optimized, however, they can be produced at a large scale. This means that synthetic biotechnology can contribute to further improvements in this field.